Featured Research

from universities, journals, and other organizations

Common diabetes treatment could extend hypoglycemia

Date:
April 8, 2014
Source:
University of Adelaide
Summary:
A common treatment for people with type 2 diabetes could cause longer-than-normal periods of the low blood sugar reaction hypoglycemia, which may result in increased health risks to people with diabetes. The treatment is the use of the peptide GLP-1 (glucagon-like peptide 1) in combination with insulin, which is now used throughout the world as a standard therapy for patients with type 2 diabetes.

Researchers at the University of Adelaide have discovered that a common treatment for people with type 2 diabetes could cause longer-than-normal periods of the low blood sugar reaction hypoglycemia, which may result in increased health risks to people with diabetes.

The treatment is the use of the peptide GLP-1 (glucagon-like peptide 1) in combination with insulin, which is now used throughout the world as a standard therapy for patients with type 2 diabetes.

A team of researchers at the University of Adelaide's School of Medicine has investigated the impact of this combination therapy on how quickly the stomach empties after eating food.

The results, now published online in the journal Diabetes Care, show that the combination of GLP-1 and insulin slows down the rate of food being emptied from the stomach.

"Low blood sugar levels usually cause the stomach to empty rapidly, however in the group studied on GLP-1 therapy it emptied no more quickly than at normal blood glucose levels," says lead author and University of Adelaide PhD student Dr Mark Plummer.

"This is a concern because it means that a significant amount of food, and therefore glucose being consumed by a diabetic patient to prevent or treat hypoglycemia, is being retained in the stomach. This would have the effect of extending hypoglycemia and potentially putting the patient at risk."

Dr Plummer says the sample group of 10 people was relatively small, "but statistically the results were significant."

"A diabetic patient really doesn't want their blood sugars to go too low because the brain requires glucose for normal functioning and you run the risk of loss of consciousness, seizures and even death in extreme cases," he says.

"There were no life-threatening effects on the patients we studied, but their symptoms included sweating, palpitations and visual disturbance."

Dr Plummer says the study highlights the potential safety implications for the combination of GLP-1 with other therapies known to induce hypoglycemia. "Further research is needed in this area. We believe there should be ongoing evaluation of this combination therapy for patients with type 2 diabetes, to better understand the risks associated with it."


Story Source:

The above story is based on materials provided by University of Adelaide. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. P. Plummer, K. L. Jones, C. E. Annink, C. E. Cousins, J. J. Meier, M. J. Chapman, M. Horowitz, A. M. Deane. Glucagon-Like Peptide 1 Attenuates the Acceleration of Gastric Emptying Induced by Hypoglycemia in Healthy Subjects. Diabetes Care, 2014; DOI: 10.2337/dc13-1813

Cite This Page:

University of Adelaide. "Common diabetes treatment could extend hypoglycemia." ScienceDaily. ScienceDaily, 8 April 2014. <www.sciencedaily.com/releases/2014/04/140408111224.htm>.
University of Adelaide. (2014, April 8). Common diabetes treatment could extend hypoglycemia. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2014/04/140408111224.htm
University of Adelaide. "Common diabetes treatment could extend hypoglycemia." ScienceDaily. www.sciencedaily.com/releases/2014/04/140408111224.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins